期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

RRM1基因表达与肺癌预后及吉西他滨耐药性的研究进展 被引量：4

The development of predicting the lung cancer prognosis and resistance to gemcitabine by the expression level of RRM1
暂未订购
导出
摘要 核糖核苷酸还原酶M1(RRM1)是DNA合成通路中的限速酶,RRM1的表达可抑制肿瘤细胞增殖,引起细胞凋亡。早期肺癌患者高RRM1表达水平提示预后较好,晚期患者高RRM1表达水平提示预后较差。RRM1是吉西他滨的分子作用靶点,是吉西他滨耐药的一个重要的预测指标,RRM1过表达者对吉西他滨化疗不敏感。 Ribonueleotide reductase M1 （RRM1） is the key enzyree in DNA synthesis pathway. RRM1 expression inhibits tumor cell proliferation and induces apoptosis. High RRM1 expressions are predictive of better survival in early NSCLC and poor survival in advanced NSCLC . RRM1 is a molecular target of gemcitabine. RRM1 expression is a crucial predictive marker in gemcitabine-resistance patients. RRM1 overexpression indicates resistance to gemcitabine.
作者 金艺凤 王莹
机构地区 皖南医学院附属弋矶山医院呼吸内科
出处 《临床肺科杂志》 2008年第10期1268-1270,共3页 Journal of Clinical Pulmonary Medicine
关键词 核苷酸还原酶类 基因表达 肺肿瘤 吉西他滨 耐药性 预后 Ribonucleotide reductases Gene expression lung neoplasms Drug resistance prognosis
分类号 R734.2 [医药卫生—肿瘤] R978.1 [医药卫生—药品]
  • 相关文献

参考文献19

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin, 2007,57 : 43 - 46.
  • 2Ramalingam S, Belani C. Systemic chemotherapy for advanced non- small cell lung cancer: recent advances and future directions. The Oncologist ,2008,13 ( supple 1 ) :5 - 13.
  • 3Torrents E, Aloy P, Gibert I, et al. Ribonucleotide reductases : divergeng evolution of an ancient enzyme. J Mol Evol,2002,55 : 138 - 152.
  • 4Cerqueira N, Fernandes P, Ramos M. Understanding ribonucleotide reductase inactivation by Gemcitabine. Chem Eur J,2007,00,0 - 0.
  • 5Zhao B, Bepler G . Transcript map and complete genomic sequnce for the 310kb region of minimal allele loss on chromosome segment 11 p15. 5 in non-small - cell lung cancer. Oncogene, 2001 ( 20 ) : 8154 - 8164.
  • 6Bepler G, Gautam a, Lauren M, et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p11.5 in non-small- cell lung cancer. J Clin Oncol,2002,20 (5) : 1353 - 1360.
  • 7Gautam A, Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Research, 2006,66: 6497 - 6502.
  • 8Gautam A, LI ZR, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene, 2003,22 ( 14 ) : 2135 - 2142.
  • 9Rosell R, Danenberg K, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in Gemcitabine/Cisplatin-treated advanced non-small-cell lung cancer patients. Cli Cancer Res, 2004,10(4) :1318 -1325.
  • 10Rosell R, Fehp E, Taron M, et al. Gene expressiol as a predictive marker of outcome in stage Ⅱ B-ⅢA-Ⅲ B non-small cell lung cancer after induction Gemcitabine-based chemotherapy followed by resectional surgery. Cli Cancer Res ,2004,10:4215s-4219s.

同被引文献31

  • 1陈芹,周彩存,张颉.ERCC1、RRM1和BRCA1在非小细胞肺癌中的表达及预后意义[J].肿瘤,2007,27(9):719-722. 被引量：57
  • 2Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [J]. CA Cancer J Clin, 2015, 65(1): 5-29. doi: 10.3322/ caae,21254.
  • 3Wang LR1, Huang MZ, Zhang GB, et aL Phase II study of gemcitabine and earboplatin in patients with advanced non- small-cell lung cancer [J]. Cancer Chemother Pharrnacol, 2007, 60(4): 601-607.
  • 4Wang L, Wu X, Huang M, et al. The efficacy and relation- ship between peak concentration and toxicity profile of fixed-dose-rate gemeitabine plus earboplatin in patients with advanced non-small-cell lung cancer [J]. Cancer Che- mother Pharmacol, 2007, 60(2): 211-218.
  • 5Gonlugur U, Pinarbasi H, Gonlugur TE, et al. The associa-tion between polymorphisms in glutathione S-transferase (GSTM1 and GSTY1) and lung cancer outcome [J]. Cancer Invest, 2006, 24(5): 497-501.
  • 6Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is as- sociated with gemcitabine resistance in non-small cell lung cancer cell lines [J]. Cancer Res, 2004, 64(11): 3761-3766.
  • 7Gray J, Simon G, Bepler G. Molecular predictors of chemo- therapy response in non-small-cell lung cancer [J]. Expert Rev Anticancer Ther, 2007, 7(4): 545-549.
  • 8Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. 1977 [J]. Biotechnology, 1992, 24: 104-108.
  • 9Chu T, Bunce K, Hogge WA, et al. Statistical model for whole genome sequencing and its application to minimally invasive diagnosis of fetal genetic disease [J]. Bioinformat- ics, 2009, 25(10): 1244-1250. doi: lO,1093/bioinformatics/ btp156.
  • 10Isla D, Sarries C, Rosell R, et al. Single nucleotide poly- morphisms and outcome in docetaxel-cisplatin-treated advanced non-small-ceU lung cancer [J]. Ann Oncol, 2004, 15(8): 1194-1203.

引证文献4

二级引证文献8

临床肺科杂志
2008年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部